Today, Pfizer announced the FDA has approved Lyrica (pregabalin) for pain associated with spinal cord injury. More than 100,000 U.S. patients with spinal cord injuries suffer from neuropathic pain and, to date, lack an adaquate treatment for their injuries.
"Until now, no FDA approved treatment options were available in the U.S. for
people with neuropathic pain associated with spinal cord injury, a condition
which can be extremely disabling," said Steven J. Romano, MD, senior vice
president and head, medicines development group, Global Primary Care Business
Unit, Pfizer. "The approval of Lyrica for this indication is a significant
milestone, exemplifying Pfizer's commitment to pursue scientific advancements
that address unmet medical needs."
Pfizer's stock (PFE) is down 0.26% in pre-market trading.